Cabaletta Bio (CABA) Stock Forecast, Price & News

Cabaletta Bio (NASDAQ:CABA) Frequently Asked Questions

Is Cabaletta Bio a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cabaletta Bio in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cabaletta Bio stock.
View analyst ratings for Cabaletta Bio or view top-rated stocks.

When is Cabaletta Bio's next earnings date?

Cabaletta Bio is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Cabaletta Bio.

How were Cabaletta Bio's earnings last quarter?

Cabaletta Bio, Inc. (NASDAQ:CABA) issued its quarterly earnings results on Thursday, May, 12th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.08.
View Cabaletta Bio's earnings history.

What price target have analysts set for CABA?

5 Wall Street analysts have issued 1-year price objectives for Cabaletta Bio's stock. Their forecasts range from $11.00 to $28.00. On average, they expect Cabaletta Bio's share price to reach $18.20 in the next year. This suggests a possible upside of 1,181.7% from the stock's current price.
View analysts' price targets for Cabaletta Bio or view top-rated stocks among Wall Street analysts.

Who are Cabaletta Bio's key executives?

Cabaletta Bio's management team includes the following people:

• Dr. Steven A. Nichtberger M.D., Co-Founder, Chairman, CEO & Pres (Age 61, Pay $871.16k)
• Dr. Gwendolyn K. Binder Ph.D., Pres of Science & Technology (Age 47, Pay $625.13k)
• Dr. David J. Chang M.D., M.P.H., Chief Medical Officer (Age 59, Pay $638.63k)
• Dr. Michael C. Milone M.D., Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
• Dr. Aimee Payne M.D., Ph.D., Co-Founder & Co-Chair of Scientific Advisory Board
• Mr. Anup Marda M.B.A., Chief Financial Officer (Age 45)
• Dr. Samik Basu M.D., Chief Scientific Officer
• Mr. Michael Gerard, Gen. Counsel
• Ms. Heather Harte-Hall M.Sc., Chief Compliance Officer
• Ms. Martha O'Connor, Chief HR Officer

Who are some of Cabaletta Bio's key competitors?

Some companies that are related to Cabaletta Bio include Scholar Rock (SRRK), Genfit (GNFT), DBV Technologies (DBVT), Fusion Pharmaceuticals (FUSN), Cellectis (CLLS), Armata Pharmaceuticals (ARMP), ARYA Sciences Acquisition Corp IV (ARYD), Fennec Pharmaceuticals (FENC), Ambrx Biopharma (AMAM), Gritstone bio (GRTS), Acumen Pharmaceuticals (ABOS), CEL-SCI (CVM), CEL-SCI (CVM), Omega Therapeutics (OMGA) and Graphite Bio (GRPH).
View all of CABA's competitors.

What other stocks do shareholders of Cabaletta Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cabaletta Bio investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Homology Medicines (FIXX), Skyworks Solutions (SWKS), CrowdStrike (CRWD), Precision BioSciences (DTIL), Invitae (NVTA) and Pfizer (PFE).

When did Cabaletta Bio IPO?

(CABA) raised $87 million in an IPO on Friday, October 25th 2019. The company issued 5,800,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Cowen and Company and Evercore Group acted as the underwriters for the IPO.

What is Cabaletta Bio's stock symbol?

Cabaletta Bio trades on the NASDAQ under the ticker symbol "CABA."

Who are Cabaletta Bio's major shareholders?

Cabaletta Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.20%), Kynam Capital Management LP (2.46%), Renaissance Technologies LLC (0.80%), Acadian Asset Management LLC (0.59%), CI Investments Inc. (0.51%) and Harbor Capital Advisors Inc. (0.48%).
View institutional ownership trends for Cabaletta Bio.

Which major investors are selling Cabaletta Bio stock?

CABA stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Virtu Financial LLC, Walleye Capital LLC, Kynam Capital Management LP, Harbor Capital Advisors Inc., Dimensional Fund Advisors LP, Hsbc Holdings PLC, and Group One Trading L.P..
View insider buying and selling activity for Cabaletta Bio or view top insider-selling stocks.

Which major investors are buying Cabaletta Bio stock?

CABA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Acadian Asset Management LLC, Vanguard Group Inc., CI Investments Inc., Veritable L.P., Powell Investment Advisors LLC, Bank of New York Mellon Corp, and Dynamic Technology Lab Private Ltd.
View insider buying and selling activity for Cabaletta Bio or or view top insider-buying stocks.

How do I buy shares of Cabaletta Bio?

Shares of CABA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cabaletta Bio's stock price today?

One share of CABA stock can currently be purchased for approximately $1.42.

How much money does Cabaletta Bio make?

Cabaletta Bio has a market capitalization of $41.15 million. The company earns $-46.29 million in net income (profit) each year or ($1.84) on an earnings per share basis.

How many employees does Cabaletta Bio have?

Cabaletta Bio employs 53 workers across the globe.

What is Cabaletta Bio's official website?

The official website for Cabaletta Bio is www.cabalettabio.com.

How can I contact Cabaletta Bio?

Cabaletta Bio's mailing address is 2929 ARCH STREET SUITE 600, PHILADELPHIA PA, 19104. The company can be reached via phone at 267-759-3100 or via email at [email protected].